bacTRL E6/E7
Alternative Names: bacTRL-E6/E7Latest Information Update: 04 Feb 2021
Price :
$50 *
At a glance
- Originator Symvivo
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Human papillomavirus infections
Most Recent Events
- 01 Feb 2021 bacTRL E6/E7 is available for licensing as of 01 Feb 2021. https://www.symvivo.com/
- 01 Feb 2021 Preclinical trials in Cancer in Canada (PO) (Symvivo pipeline, February 2021)
- 01 Feb 2021 Preclinical trials in Human papillomavirus infections in Canada (PO) (Symvivo pipeline, February 2021)